OncoMatch/Clinical Trials/NCT06868849
A Study of JMT203 in Patients With Cancer Cachexia
Is NCT06868849 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies JMT203 for non small cell lung cancer.
Treatment: JMT203 — A Phase Ia/II, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of JMT203 in Patients with Cancer Cachexia
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Pancreatic Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: parenteral nutrition
Patients receiving tube feeding or parenteral nutrition therapy during the screening period
Lab requirements
Blood counts
Adequate organ function, meeting relevant laboratory test standards (without transfusion or hematopoietic growth factor support within 14 days prior to testing)
Kidney function
Adequate organ function, meeting relevant laboratory test standards (without transfusion or hematopoietic growth factor support within 14 days prior to testing)
Liver function
Adequate organ function, meeting relevant laboratory test standards (without transfusion or hematopoietic growth factor support within 14 days prior to testing)
Adequate organ function, meeting relevant laboratory test standards (without transfusion or hematopoietic growth factor support within 14 days prior to testing)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06868849 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior parenteral nutrition disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify